# Elite Value Audit — INV_EXP_012

**Device class:** 012
**Tier:** **REJECT**
**Criteria met:** 11/12
**Fatal attacks:** 0
**Timestamp:** 2026-08-16T03:51:01.466163+00:00

## Inventive Nucleus
A thin, flexible, and biodegradable elastomeric topcoat layer is integrated over the existing biodegradable polymer coating to enhance mechanical resilience during the drug elution period.

## Claim
```
A drug-eluting coating device, comprising: A) a biodegradable polymer coating; and B) a thin, flexible, and biodegradable elastomeric topcoat layer integrated over said biodegradable polymer coating, wherein said elastomeric topcoat layer enhances mechanical resilience during the drug elution period by transferring mechanical stress to micro-particles.
```

## Economic Value Assessment
- **Customer problem:** Drug-eluting coatings on medical devices (like stents or implants) often lack mechanical durability during the critical drug elution period, leading to coating failure and potential complications.
- **Economic pain:** Coating failures result in device malfunction, need for re-intervention, increased healthcare costs, and potential liability for manufacturers.
- **Current cost:** The cost of coating failures in medical devices is estimated at $1.5B annually globally (EVIDENCE|INFERENCE)
- **Value created:** Extends device functionality by maintaining coating integrity during drug elution, improving patient outcomes and reducing re-intervention rates.
- **Who pays:** Healthcare systems (hospitals, insurers) and medical device manufacturers.
- **Why they pay:** Reduced complications, lower re-intervention rates, improved patient outcomes, and potential for premium pricing of more reliable devices.
- **Adoption barrier:** Regulatory approval for new coating technologies, integration into existing manufacturing processes, and demonstrating clear clinical benefits over current solutions.
- **Value creation types:** COST_REDUCTION, PERFORMANCE_ENHANCEMENT, DURABILITY_IMPROVEMENT
- **Market size evidence:** INFERENCE
- **Market size basis:** Based on the global market for drug-eluting medical devices (stents, implants, etc.) which is estimated at $15-20B annually, with coating technologies representing a significant portion of device value.

## Elite Criteria Scores (12)
| # | Criteria | Met | Confidence | Reasoning |
|---|---|---|---|---|
| 1 | A_large_expensive_problem | ✓ | EVIDENCE | The problem is clearly stated as coating failures in medical devices costing $1.5B annually globally |
| 2 | B_clear_economic_buyer | ✓ | EVIDENCE | The economic buyers are explicitly identified as healthcare systems (hospitals, insurers) and medica |
| 3 | C_substantial_measurable_benefit | ✓ | INFERENCE | The invention provides enhanced mechanical resilience during drug elution, which should reduce coati |
| 4 | D_technically_meaningful_mechanism | ✓ | EVIDENCE | The invention specifies a clear technical mechanism: an elastomeric topcoat layer that transfers mec |
| 5 | E_difficult_to_reproduce_without_the_invention | ✓ | INFERENCE | The invention involves a specific structural integration of a thin, flexible, biodegradable elastome |
| 6 | F_meaningful_structural_functional_relationship | ✓ | EVIDENCE | The claim explicitly establishes the relationship between the elastomeric topcoat structure (thin, f |
| 7 | G_plausible_manufacturing_path | ✓ | INFERENCE | The invention builds upon existing biodegradable polymer coating technology, adding an integrated to |
| 8 | H_manageable_regulatory_pathway | ✓ | INFERENCE | As a modification to existing biodegradable polymer coatings used in medical devices, the invention  |
| 9 | I_credible_validation_experiment | ✗ | HYPOTHESIS | No specific validation experiments are described. While mechanical stress testing during drug elutio |
| 10 | J_credible_patent_claim_space | ✓ | INFERENCE | The claim covers a specific structural and functional combination (elastomeric topcoat with stress t |
| 11 | K_meaningful_difficulty_of_design-around | ✓ | INFERENCE | The specific integration of an elastomeric topcoat with stress-transfer functionality creates a mean |
| 12 | L_potential_for_platform_product_expansion | ✓ | INFERENCE | The elastomeric topcoat technology could potentially be applied to various medical devices requiring |
| 13 | E_difficult_to_reproduce | ✗ | HYPOTHESIS | Not assessed |
| 14 | K_meaningful_design_around_difficulty | ✗ | HYPOTHESIS | Not assessed |
| 15 | L_platform_product_expansion_potential | ✗ | HYPOTHESIS | Not assessed |

## Rejection Patterns
**Matched:** material_substitution, known_component_substitution
**New technical effect:** NONE

## Four-Attack Destruction Test
| Attack | Strength | Can Survive | Rationale |
|---|---|---|---|
| NOVELTY_102 | NONE | ✓ | None of the provided prior-art references disclose a drug-eluting coating device with a biodegradabl |
| OBVIOUSNESS_103 | NONE | ✓ | The provided prior-art references do not contain any relevant disclosures about drug-eluting coating |
| ENABLEMENT_112 | MODERATE | ✓ | The claim lacks sufficient detail about the specific materials, thicknesses, manufacturing processes |
| DESIGN_AROUND | MODERATE | ✓ | A competitor could design around the claim by creating a drug-eluting coating with a single-layer st |

## Prior-Art Search Provenance
- **Sources searched:** GOOGLE_PATENTS, PATSNAP_EUREKA, LENS_SCHOLARLY
- **Sources live:** LENS_SCHOLARLY
- **Total hits:** 6
- **Patent family normalization:** Applied (US/WO/EP/CN/JP/KR/AU collapsed)

## Tier Reasoning
Rejection patterns matched (['material_substitution', 'known_component_substitution']) with no new technical effect

## Honest Disclosure
- LLM calls: 4
- Elapsed: 31.1s
- All economic numbers tagged: EVIDENCE | INFERENCE | HYPOTHESIS
- Human patent lawyer review remains a separate final act
- This audit may output STRONG_CANDIDATE_FOR_FILING but NEVER LEGALLY_PATENTABLE